Assessing the impact of nintedanib and pirfenidone on lung function in idiopathic pulmonary fibrosis: a comprehensive meta-analysis
Abstract
Background/Aim. The incidence of idiopathic pulmonary fibrosis (IPF) has been increasing each year. Although pirfenidone and nintedanib were approved in 2014, they received only conditional recommendations, and no medication has yet been strongly endorsed for IPF treatment. The aim of the study was to compare the safety and efficacy of pirfenidone and nintedanib. Methods. All randomized and non-randomized clinical trials were identified by searching databases for published studies, including Medline, Embase, Scopus, Google Scholar, and ClinicalTrials.gov. A meta-analysis was conducted to evaluate the impact of pirfenidone and nintedanib on clinical outcomes and safety. Patients treated with pirfenidone were compared with those treated with nintedanib. Results. This study included twelve papers. Both pirfenidone and nintedanib were found to significantly reduce the decline in mean forced vital capacity (FVC) and mean diffusion capacity of the lungs for carbon monoxide (DLco) at 6 and 12 months. No significant difference was observed between pirfenidone and nintedanib in terms of improvement in FVC or DLco. Similarly, both antifibrotic agents had similar safety profiles. However, patients receiving nintedanib experienced significantly fewer instances of diarrhea (p < 0.00001) compared to those receiving pirfenidone, whereas patients receiving pirfenidone experienced significantly fewer instances of skin rash (p < 0.00001) compared with those receiving nintedanib. Conclusion. Potential differences between pirfenidone and nintedanib can be inferred from the effectiveness ranking derived from this meta-analysis. Further direct comparative studies are necessary to explore this issue, which will help us better understand the potential of combinatorial, sequential, or adjunctive treatment regimens in which both antifibrotic agents might play a crucial role for a specific group of IPF patients.
References
Crystal RG, Bitterman PB, Mossman B, Schwarz MI, Sheppard D, Almasy L, et al. Future research directions in idiopathic pul-monary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med 2002; 166(2): 236–46. DOI: 10.1164/rccm.2201069.
Kandhare AD, Mukherjee AA, Ghosh P, Bodhankar SL. Efficacy of antioxidant in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. EXCLI J 2016; 15: 636–51. DOI: 10.17179/excli2016-619.
Kaminski N. Microarray analysis of idiopathic pulmonary fi-brosis. Am J Respir Cell Mol Biol 2003; 29(1 Suppl): S32–6. DOI:10.1165/rcmb.2003-0159SU.
JanWillem D, Lin C, Moog S, Jaillet M, Castier Y, Cazes A, et al. CCAAT/enhancer binding protein delta (C/EBPdelta) defi-ciency does not affect bleomycin-induced pulmonary fibrosis. J Clin Transl Res 2018; 3(Suppl 2): 358–65. DOI: 10.18053/jctres.03.2017S2.004.
Khalil N, O'Connor R. Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment. CMAJ 2004; 171(2): 153–60. DOI: 10.1503/cmaj.1030055.
Nagra N, Penna R, La Selva D, Coy D, Siddique A, Burman B. Tagging incidental finding of fatty liver on ultrasound: A nov-el intervention to improve early detection of liver fibrosis. J Clin Transl Res 2021; 7(5): 641–7. DOI: 10.18053/jctres.07.202105.009.
Zhou Z, Kandhare AD, Kandhare AA, Bodhankar SL. Hesperidin ameliorates bleomycin-induced experimental pulmonary fibro-sis via inhibition of TGF-β1/Smad3/AMPK and IkappaBal-pha/NF-kappaB pathways. EXCLI J 2019; 18: 723-45. DOI: 10.17179/excli2019-1094.
Akter F, Araf Y, Promon SK, Zhai J, Zheng C. 3D Bioprinting for Regenerating COVID-19-Mediated Irreversibly Damaged Lung Tissue. Int J Bioprint 2022; 8(4): 616. DOI: 10.18063/ijb.v8i4.616.
Ng WL, Ayi TC, Liu YC, Sing SL, Yeong WY, Tan BH. Fabri-cation and Characterization of 3D Bioprinted Triple-layered Human Alveolar Lung Models. Int J Bioprint 2021; 7(2): 332. DOI: 10.18063/ijb.v7i2.332.
Kivrak T, Karasu M, Karaca O, Koca SS. Cardiovascular Evalua-tion in Patients with Systemic Sclerosis in the Turkish Popula-tion. INNOSC Theranostics Pharmacol Sci 2023; 6(1): 22–7. DOI: 10.36922/itps.348.
Raghu G. Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches. Eur Respir J 2006; 28(3): 463–5. DOI: 10.1183/09031936.06.00086606.
Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Anti-fibrotic activities of pirfenidone in animal models. Eur Respir Rev 2011; 20(120): 85–97. DOI: 10.1183/09059180.00001111.
Didiasova M, Singh R, Wilhelm J, Kwapiszewska G, Wujak L, Zakrzewicz D, et al. Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors. FASEB J 2017; 31(5): 1916–28. DOI: 10.1096/fj.201600892RR.
Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35(4): 821–9. DOI: 10.1183/09031936.00005209.
Carter NJ. Pirfenidone: in idiopathic pulmonary fibrosis. Drugs 2011; 71(13): 1721–32. DOI: 10.2165/11207710-000000000-00000.
Dudhat KR. Impact of COVID-19 Pandemic on Cancer Pa-tients with Pulmonary Fibrosis on Chemosurveillance. INNOSC Theranostics Pharmacol Sci 2023; 6(1): 15–21. DOI: 10.36922/itps.252.
Rogliani P, Calzetta L, Cavalli F, Matera MG, Cazzola M. Pirfenidone, nintedanib and N-acetylcysteine for the treat-ment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Pulm Pharmacol Ther 2016; 40: 95–103. DOI: 10.1016/j.pupt.2016.07.009.
Kadam SS, Kadam T. Cystic hygroma in a young adult: A case report and recent management. Tumor Discov 2022; 1(2): 151. DOI: 10.36922/td.v1i2.151.
Margulis AV, Pladevall M, Riera-Guardia N, Varas-Lorenzo C, Hazell L, Berkman ND, et al. Quality assessment of observa-tional studies in a drug-safety systematic review, comparison of two tools: the Newcastle–Ottawa scale and the RTI item bank. Clin Epidemiol 2014; 6: 359–68. DOI: 10.2147/CLEP.S66677.
Cioffi I, Farella M. Quality of randomised controlled trials in dentistry. Int Dent J 2011; 61(1): 37–42. DOI: 10.1111/j.1875-595X.2011.00007.x.
Bargagli E, Piccioli C, Rosi E, Torricelli E, Turi L, Piccioli E, et al. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre. Pulmonology 2019; 25(3): 149–53. DOI: 10.1016/j.pulmoe.2018.06.003.
Burgos MM, Trueba MM, Corrales TD. 4CPS-123 Antifibrotic s in idiopathic pulmonary fibrosis management: pirfenidone and nintedanib. Eur J Hospital Pharm 2019; 26: A125–6. DOI:10.1136/ejhpharm-2019-eahpconf.272.
Belhassen M, Dalon F, Nolin M, Van Ganse E. Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis. Respir Res 2021; 22(1): 135. DOI: 10.1186/s12931-021-01714-y.
Cameli P, Refini RM, Bergantini L, d'Alessandro M, Alonzi V, Magnoni C, et al. Long-Term Follow-Up of Patients With Idi-opathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study. Front Mol Biosci 2020; 7: 581828. DOI: 10.3389/fmolb.2020.581828.
Cerri S, Monari M, Guerrieri A, Donatelli P, Bassi I, Garuti M, et al. Real-life comparison of pirfenidone and nintedanib in pa-tients with idiopathic pulmonary fibrosis: A 24-month assess-ment. Respir Med 2019; 159: 105803. DOI: 10.1016/j.rmed.2019.105803.
Feng H, Zhao Y, Li Z, Kang J. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia pa-tients. Ther Adv Respir Dis 2020; 14: 1753466620963015. DOI: 10.1177/1753466620963015.
Fournier D, Jouneau S, Bouzillé G, Polard E, Osmont MN, Scail-teux LM. Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients. Pulm Pharmacol Ther 2022; 76: 102149. DOI: 10.1016/j.pupt.2022.102149.
Kerget B, Çil G, Araz Ö, Alper F, Akgün M. Comparison of two antifibrotic treatments for lung fibrosis in post-COVID-19 syndrome: A randomized, prospective study. Medicina Clinica (Barc) 2023; 160(12): 525–30. DOI: 10.1016/j.medcli.2022.12.021.
Khan MA, Sherbini N, Alyami S, Al-Harbi A, Al-Ghamdi M, Alrajhi S, et al. Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh: Real-life data. Ann Thorac Med 2023; 18(1): 45–51. DOI: 10.4103/atm.atm_206_22.
Marijic P, Schwarzkopf L, Schwettmann L, Ruhnke T, Trudzinski F, Kreuter M. Pirfenidone vs. nintedanib in patients with idio-pathic pulmonary fibrosis: a retrospective cohort study. Respir Res 2021; 22(1): 268. DOI: 10.1186/s12931-021-01857-y.
Moor CC, Mostard RLM, Grutters JC, Bresser P, Aerts J, Dirksen CD, et al. Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fi-brosis: a quantitative study. Respir Res 2020; 21(1): 196. DOI: 10.1186/s12931-020-01458-1.
Ntolios P, Archontogeorgis K, Anevlavis S, Bonelis K, Paxinou N, Voulgaris A, et al. Feasibility and safety of treatment switch from Pirfenidone to Nintedanib in patients with idiopathic pulmonary fibrosis: a real-world observational study. Eur Rev Med Pharmacol Sci 2021; 25(20): 6326–32. DOI: 10.26355/eurrev_202110_27004.
Lv H, Song H, Qin Z, Xing R, Chen Y. Underexpression of SCN7A is associated with poor prognosis in lung adenocarci-noma. Gene Protein Dis 2023; 2(1): 363. DOI: 10.36922/gpd.363
Zhang Z, Xu W, Sheng H, Huang L, Zhang J, Zhang L, et al. Hematoma clearance by reactive microglia after intracerebral hemorrhage. Gene Protein Dis 2023; 2(2): 336. DOI: https://doi.org/10.36922/gpd.336
Wu WJ, Huang WM, Liang CH, Yun CH. Pulmonary vascular volume is associated with DLCO and fibrotic score in idio-pathic pulmonary fibrosis: an observational study. BMC Med Imaging 2022; 22(1): 76. DOI: 10.1186/s12880-022-00803-8.
Cheung K, Askari S, Allen MD. A novel approach to mitigate muscle atrophy in Guillain-Barre syndrome. Adv Neuro 2023; 2(2): 280. DOI:10.36922/an.280.
Visnagri A, Kandhare AD, Ghosh P, Bodhankar SL. Endothelin receptor blocker bosentan inhibits hypertensive cardiac fibro-sis in pressure overload-induced cardiac hypertrophy in rats. Cardiovasc Endocrinol 2013; 2(4): 85–97. DOI:10.1097/XCE.0000000000000010.
Aswar U, Mahajan U, Kandhare A, Aswar M. Ferulic acid ame-liorates doxorubicin-induced cardiac toxicity in rats. Naunyn Schmiedebergs Arch Pharmacol 2019; 392(6): 659–68. DOI: 10.1007/s00210-019-01623-4.
Jin YC, Wu MQ, Chen KZ, Wang J. Role of circulating tumor DNA in the management of patients with non-small cell lung cancer. Global Transl Med 2022; 1(1): 1–13. DOI:10.36922/gtm.v1i1.96.
Sun H, Deng K, Zhou X, Cao D, Cheng Y, Chen X, et al. A novel gene prognostic signature lymphocyte cytosolic protein 2 regu-lates melanoma progression by activating tumor-infiltrating CD8+ T-cells through the interferon regulatory factor 5 sig-naling pathway. Tumor Discovery 2023; 2(1): 318. DOI:10.36922/td.318.
Lee SH, Park JS, Kim SY, Kim DS, Kim YW, Chung MP, et al. Clinical features and prognosis of patients with idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Int J Tuberc Lung Dis 2019; 23(6): 678–84. DOI: 10.5588/ijtld.18.0194
Malyutina S, Maximov V, Chervova O, Orlov P, Voloshin V, Rya-bikov A, et al. Leukocyte telomere length and mitochondrial DNA copy number association with colorectal cancer risk in an aging population. Global Transl Med 2023; 2(1). DOI: 10.36922/gtm.v2i1.184.
Knüppel L, Ishikawa Y, Aichler M, Heinzelmann K, Hatz R, Behr J, et al. A novel antifibrotic mechanism of nintedanib and pirfenidone. Inhibition of collagen fibril assembly. Am J Respir Cell Mol Biol 2017; 57(1): 77–90. DOI: 10.1165/rcmb.2016-0217OC.
Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Antifi-brotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 2014; 349(2): 209–20. DOI: 10.1124/jpet.113.208223.
Kandhare AD, Bodhankar SL, Mohan V, Thakurdesai PA. Glyco-sides Based Standardized Fenugreek Seed Extract Ameliorates Bleomycin-induced Liver Fibrosis in Rats Via Modulation of Endogenous Enzymes. J Pharm Bioallied Sci 2017; 9(3): 185–94. DOI: 10.4103/0975-7406.214688.
Kandhare AD, Alam J, Patil MV, Sinha A, Bodhankar SL. Wound healing potential of naringin ointment formulation via regulating the expression of inflammatory, apoptotic and growth mediators in experimental rats. Pharm Biol 2016; 54(3): 419–32. DOI: 10.3109/13880209.2015.1038755.
Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, et al. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (IN-MARK study): a randomised, placebo-controlled study. Lan-cet Respir Med 2019; 7(9): 771–9. DOI: 10.1016/S2213-2600(19)30255-3.
Kolb M, Richeldi L, Behr J, Maher TM, Tang W, Stowasser S, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax 2017; 72(4): 340–6. DOI: 10.1136/thoraxjnl-2016-208710.
Roach K, Castells E, Dixon K, Mason S, Elliott G, Marshall H, et al. Evaluation of pirfenidone and nintedanib in a human lung model of fibrogenesis. Front Pharmacol 2021; 12: 679388. DOI: 10.3389/fphar.2021.679388.
Ghule AE, Kandhare AD, Jadhav SS, Zanwar AA, Bodhankar SL. Omega-3-fatty acid adds to the protective effect of flax lignan concentrate in pressure overload-induced myocardial hyper-trophy in rats via modulation of oxidative stress and apopto-sis. Int Immunopharmacol 2015; 28(1): 751–63. DOI: 10.1016/j.intimp.2015.08.005.